Article
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
array:22 [ "pii" => "S2253808918300028" "issn" => "22538089" "doi" => "10.1016/j.remnie.2017.12.008" "estado" => "S300" "fechaPublicacion" => "2018-03-01" "aid" => "966" "copyrightAnyo" => "2018" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Rev Esp Med Nucl Imagen Mol. 2018;37:71-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 4 "formatos" => array:2 [ "HTML" => 2 "PDF" => 2 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X17303153" "issn" => "2253654X" "doi" => "10.1016/j.remn.2017.12.007" "estado" => "S300" "fechaPublicacion" => "2018-03-01" "aid" => "966" "copyright" => "Elsevier España, S.L.U. y SEMNIM" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Rev Esp Med Nucl Imagen Mol. 2018;37:71-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 210 "formatos" => array:2 [ "HTML" => 152 "PDF" => 58 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Evolución de la Medicina Nuclear en el diagnóstico y tratamiento de pacientes con cáncer de próstata" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "71" "paginaFinal" => "72" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Evolution of Nuclear Medicine in the diagnosis and treatment of prostate cancer" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.J. García Velloso, M. Rodríguez Fraile" "autores" => array:2 [ 0 => array:2 [ "nombre" => "M.J." "apellidos" => "García Velloso" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Rodríguez Fraile" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2253808918300028" "doi" => "10.1016/j.remnie.2017.12.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918300028?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X17303153?idApp=UINPBA00004N" "url" => "/2253654X/0000003700000002/v1_201803020432/S2253654X17303153/v1_201803020432/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2253808917302070" "issn" => "22538089" "doi" => "10.1016/j.remnie.2017.12.003" "estado" => "S300" "fechaPublicacion" => "2018-03-01" "aid" => "939" "copyright" => "Elsevier España, S.L.U. y SEMNIM" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2018;37:73-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 4 "formatos" => array:2 [ "HTML" => 2 "PDF" => 2 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline <span class="elsevierStyleSup">18</span>F-FDG PET/CT in breast cancer with neoadjuvant chemotherapy indication" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "73" "paginaFinal" => "79" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Papel predictivo y pronóstico de las variables volumétricas metabólicas obtenidas en la <span class="elsevierStyleSup">18</span>F-FDG PET/TC en cáncer de mama con indicación de quimioterapia adyuvante" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1617 "Ancho" => 3084 "Tamanyo" => 263673 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">52-year-old female with triple negative invasive ductal carcinoma, stage T2NxM1 by <span class="elsevierStyleSup">18</span>F-FDG PET/CT. (A) Maximum intensity projection of a <span class="elsevierStyleSup">18</span>F-FDG-PET/CT image that represents a left breast tumor and multiple physiological brown fat deposits in the cervical and paraspinal regions. (B) Axial <span class="elsevierStyleSup">18</span>F-FDG-PET/CT, (C) CT and (D) co-registration of these that show a right lung nodule with FDG avidity. (E) Breast tumor in <span class="elsevierStyleSup">18</span>F-FDG-PET/CT and CT co-registered axial projection. (F) Breast tumor voxels after 3D segmentation using a code developed and implemented in-house at MATLAB and (G) lesion reconstruction. After neoadjuvant chemotherapy no complete histological response of breast tumor was achieved although the pulmonary nodule disappeared. Patient was in DFs during follow-up (OS and DFS of 40 months).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A.M. Garcia-Vicente, J. Pérez-Beteta, M. Amo-Salas, D. Molina, G.A. Jimenez-Londoño, A.M. Soriano-Castrejón, F.J. Pena Pardo, A. Martínez-González" "autores" => array:8 [ 0 => array:2 [ "nombre" => "A.M." "apellidos" => "Garcia-Vicente" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Pérez-Beteta" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Amo-Salas" ] 3 => array:2 [ "nombre" => "D." "apellidos" => "Molina" ] 4 => array:2 [ "nombre" => "G.A." "apellidos" => "Jimenez-Londoño" ] 5 => array:2 [ "nombre" => "A.M." "apellidos" => "Soriano-Castrejón" ] 6 => array:2 [ "nombre" => "F.J." "apellidos" => "Pena Pardo" ] 7 => array:2 [ "nombre" => "A." "apellidos" => "Martínez-González" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X17301300" "doi" => "10.1016/j.remn.2017.09.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X17301300?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808917302070?idApp=UINPBA00004N" "url" => "/22538089/0000003700000002/v1_201803020417/S2253808917302070/v1_201803020417/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Evolution of nuclear medicine in the diagnosis and treatment of prostate cancer" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "71" "paginaFinal" => "72" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M.J. García Velloso, M. Rodríguez Fraile" "autores" => array:2 [ 0 => array:4 [ "nombre" => "M.J." "apellidos" => "García Velloso" "email" => array:1 [ 0 => "mjgarciave@unav.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Rodríguez Fraile" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Grupo de Trabajo de Oncología de la Sociedad Española de, Medicina Nuclear e Imagen Molecular, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evolución de la Medicina Nuclear en el diagnóstico y tratamiento de pacientes con cáncer de próstata" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Prostate cancer (PC) is among the most prevalent cancers worldwide and is the third cause of cancer-associated death in men.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> In patients with localized disease undergoing radical prostatectomy with intention to cure, biochemical relapse is defined as two consecutive elevations in the prostate-specific antigen (PSA)<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>0.2<span class="elsevierStyleHsp" style=""></span>ng/ml, while in patients receiving radiotherapy it is defined as an increase<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>2<span class="elsevierStyleHsp" style=""></span>ng/ml compared to the nadir PSA value.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Diagnostic imaging techniques play an important role in the evaluation of patients with PC, not only in the study of initial extension but also in the detection of disease recurrence and assessment of response to treatment. The molecular imaging modality of positron emission tomography/computerized tomography (PET/CT) provides diagnostic information in patients with cancer. Although fluorine-18 fluorodeoxyglucose (<span class="elsevierStyleSup">18</span>F-FDG) has shown to be useful in a large variety of tumors, the results obtained in patients with PC are limited, being more frequently used in patients with aggressive (Gleason score<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>8) or undifferentiated tumors. This is largely because tumors usually present low avidity for <span class="elsevierStyleSup">18</span>F-FDG, and their uptake may overlap with that presented by benign lesions or even a healthy prostate.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The introduction of choline labeled with carbon-11 or <span class="elsevierStyleSup">18</span>F was an advance in the follow-up of patients with PC since it was found to be effective in the detection of recurrence with PSA values well below the established cut-off for conventional imaging techniques.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> However, its low sensitivity in patients with PSA values<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1<span class="elsevierStyleHsp" style=""></span>ng/ml led to questions about its indication in patients with a PSA level under this value.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Several studies have demonstrated that the kinetics of PSA (velocity and doubling time) and not only its absolute value can predict a positive result with PET-choline. Therefore, a PSA doubling time of less than 6 months or a velocity greater than 1<span class="elsevierStyleHsp" style=""></span>ng/ml/year help to select patients with low PSA values but who may benefit from this study.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a> Nonetheless, further studies are needed to define the ideal candidates for PET-choline in the study of recurrence.</p><p id="par0020" class="elsevierStylePara elsevierViewall">In the initial staging of PC different studies have shown that although its specificity is high, the sensitivity is low, and therefore its use is only recommended in patients with a high risk of lymph node involvement according to staging nomograms.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,9</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Therefore, in the last two decades, the need for radiotracers with greater accuracy for extension studies in patients with PC and for early localization of biochemical relapse with low PSA values has led to the development of low molecular weight ligands labeled with <span class="elsevierStyleSup">68</span>Ga, <span class="elsevierStyleSup">18</span>F, <span class="elsevierStyleSup">89</span>Zr and <span class="elsevierStyleSup">99m</span>Tc which bind with high affinity to the receptor of the prostate-specific membrane antigen (PSMA). The most widely used and validated is <span class="elsevierStyleSup">68</span>Ga-PSMA, a new radiotracer with greater sensitivity and specificity than choline analogs in patients with PSA values <1<span class="elsevierStyleHsp" style=""></span>ng/ml. The European and American societies of nuclear medicine have recently published guidelines for the use of PET/CT with <span class="elsevierStyleSup">68</span>Ga-PSMA,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> and therefore this subject has been chosen for continuing education in this issue of REMNIM.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">11</span></a> PSMA is a transmembrane glycoprotein which is highly overexpressed in 90–95% of the cases of PC.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> The PSMA gene is localized in the short arm of chromosome 11, and dysplastic and neoplastic changes induce PSMA expression on the luminal surface of the prostatic ducts. Overexpression increases with the tumor grade and stage and overall in progression, with the development of resistance to castration. Therefore, PSMA may have excellent benefits in all the stages of PC: not only in the diagnosis of the primary tumor but also in the initial staging, the detection of biochemical relapse even in patients with low PSA levels and in the selection of patients who are candidates for metabolic therapy with PSMA labeled with α or β emitters.</p><p id="par0030" class="elsevierStylePara elsevierViewall">The clinical use of PSMA ligands labeled with isotopes for diagnosis and therapy has shown unprecedented acceptance as shown by the growing number of publications.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> The current evidence in the literature indicates that molecular imaging with PSMA may considerably influence early treatment of recurrence as well as in the study of initial extension of intermediate- and high-risk tumors.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> The first results demonstrated the utility of <span class="elsevierStyleSup">177</span>Lu-PSMA in metabolic radiotherapy in patients with advanced disease, and new advances are expected with the use of α emitters. The potentiation of clinical applications of these ligands are described in the study by Cucurullo et al.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">15</span></a> We are now witnessing a new era of precision medicine and the strategy of teragnosis by “imaging and treatment” with new radiolabeled ligands, and PSMA has the potential to detect recurrence early in patients with PC and thereby contribute to improving their survival. In the Clinical Note, Tuncel and Telli present an example of the diagnostic value and therapeutic efficacy of PSMA in a patient with castration-resistant metastatic disease.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> For adequate evaluation of response they needed to evaluate not only the diagnostic images obtained with <span class="elsevierStyleSup">68</span>Ga-PSMA PET/CT but also the post-therapy images with <span class="elsevierStyleSup">177</span>Lu-PSMA and the PSA values.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Nonetheless, <span class="elsevierStyleSup">68</span>Ga-PSMA does not detect all recurrences, and other types of cancer also express PSMA. Neither has it been investigated whether <span class="elsevierStyleSup">68</span>Ga-PSMA detects well differentiated tumors better than choline analogs and undifferentiated tumors better than <span class="elsevierStyleSup">18</span>F-FDG. In addition, the data available are predominantly based on retrospective analyses, and thus, well defined cohorts of patients are needed, with studies designed to endorse their approval by drug regulating agencies and their clinical implementation. Fortunately, prospective studies which may provide the necessary evidence are currently ongoing. In parallel, there have been considerable technological advances in the detection equipment with the incorporation of PET/MR.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,18</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Interdisciplinary collaboration is necessary to establish the clinical indications of these new technologies and achieve better diagnosis and treatment of patients with PC.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: García Velloso MJ, Rodríguez Fraile M. Evolución de la Medicina Nuclear en el diagnóstico y tratamiento de pacientes con cáncer de próstata. Rev Esp Med Nucl Imagen Mol. 2018;37:71–72.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:18 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global cancer statistics, 2012" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L.A. Torre" 1 => "F. Bray" 2 => "R.L. Siegel" 3 => "J. Ferlay" 4 => "J. Lortet-Tieulent" 5 => "A. Jemal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3322/caac.21262" "Revista" => array:6 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2015" "volumen" => "65" "paginaInicial" => "87" "paginaFinal" => "108" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25651787" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Cornford" 1 => "J. Bellmunt" 2 => "M. Bolla" 3 => "E. Briers" 4 => "M. de Santis" 5 => "T. Gross" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2016.08.002" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2017" "volumen" => "71" "paginaInicial" => "630" "paginaFinal" => "642" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27591931" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Is there use for FDG-PET in prostate cancer?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "H. Jadvar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.semnuclmed.2016.07.004" "Revista" => array:6 [ "tituloSerie" => "Semin Nucl Med" "fecha" => "2016" "volumen" => "46" "paginaInicial" => "502" "paginaFinal" => "506" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27825430" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate cancer, version 1.2016" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.L. Mohler" 1 => "A.J. Armstrong" 2 => "R.R. Bahnson" 3 => "A.V. D’Amico" 4 => "B.J. Davis" 5 => "J.A. Eastham" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Natl Compr Cancer Netw" "fecha" => "2016" "volumen" => "14" "paginaInicial" => "19" "paginaFinal" => "30" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dual tracer <span class="elsevierStyleSup">11</span>C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.A. Richter" 1 => "M. Rodríguez" 2 => "J. Rioja" 3 => "I. Peñuelas" 4 => "J. Martí-Climent" 5 => "P. Garrastachu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11307-009-0243-y" "Revista" => array:7 [ "tituloSerie" => "Mol Imaging Biol" "fecha" => "2010" "volumen" => "12" "paginaInicial" => "210" "paginaFinal" => "217" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19543774" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1470204510702746" "estado" => "S300" "issn" => "14702045" ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "L. Evangelista" 1 => "A. Guttilla" 2 => "F. Zattoni" 3 => "P.C. Muzzio" 4 => "F. Zattoni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2012.09.039" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2013" "volumen" => "63" "paginaInicial" => "1040" "paginaFinal" => "1048" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23036576" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PET/CT with <span class="elsevierStyleSup">11</span>C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Fanti" 1 => "S. Minozzi" 2 => "P. Castellucci" 3 => "S. Balduzzi" 4 => "K. Herrmann" 5 => "B.J. Krause" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-015-3202-7" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2016" "volumen" => "43" "paginaInicial" => "55" "paginaFinal" => "69" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26450693" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of prostate cancer with <span class="elsevierStyleSup">11</span>C- and <span class="elsevierStyleSup">18</span>F-choline PET/CT: diagnosis and initial staging" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Nitsch" 1 => "O.W. Hakenberg" 2 => "M. Heuschkel" 3 => "D. Dräger" 4 => "G. Hildebrandt" 5 => "B.J. Krause" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2967/jnumed.115.169748" "Revista" => array:6 [ "tituloSerie" => "J Nucl Med" "fecha" => "2016" "volumen" => "57" "paginaInicial" => "38S" "paginaFinal" => "42S" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27694169" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PET tracers beyond FDG in prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.M. Schuster" 1 => "C. Nanni" 2 => "S. Fanti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.semnuclmed.2016.07.005" "Revista" => array:6 [ "tituloSerie" => "Semin Nucl Med" "fecha" => "2016" "volumen" => "46" "paginaInicial" => "507" "paginaFinal" => "521" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27825431" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleSup">68</span>Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W.P. Fendler" 1 => "M. Eiber" 2 => "M. Beheshti" 3 => "J. Bomanji" 4 => "F. Ceci" 5 => "S. Cho" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-017-3670-z" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2017" "volumen" => "44" "paginaInicial" => "1014" "paginaFinal" => "1024" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28283702" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0095" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "On behalf of the oncology task force of spanish society of nuclear medicine and molecular imaging. La PET/TC con <span class="elsevierStyleSup">68</span>Ga-PSMA en el cáncer de próstata" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.R. García Garzón" 1 => "M. de Arcocha Torres" 2 => "R. Delgado-Bolton" 3 => "F. Ceci" 4 => "S. Alvarez Ruiz" 5 => "J. Orcajo Rincón" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Esp Med Nucl Imagen Mol" "fecha" => "2018" "volumen" => "37" "paginaInicial" => "130" "paginaFinal" => "138" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathological and molecular aspects of prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.M. DeMarzo" 1 => "W.G. Nelson" 2 => "W.B. Isaacs" 3 => "J.I. Epstein" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(03)12779-1" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2003" "volumen" => "361" "paginaInicial" => "955" "paginaFinal" => "964" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12648986" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleSup">68</span>Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F.E. von Eyben" 1 => "M. Picchio" 2 => "R. von Eyben" 3 => "H. Rhee" 4 => "G. Bauman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Eur Urol Focus" "fecha" => "2016" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sensitivity, specificity, and predictors of positive <span class="elsevierStyleSup">68</span>Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Perera" 1 => "N. Papa" 2 => "D. Christidis" 3 => "D. Wetherell" 4 => "M.S. Hofman" 5 => "D.G. Murphy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2016.06.021" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2016" "volumen" => "70" "paginaInicial" => "926" "paginaFinal" => "937" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27363387" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0100" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Will <span class="elsevierStyleSup">68</span>Ga PSMA-radioligands be the only choice for Nuclear Medicine in Prostate Cancer in the near future? A clinical update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "V. Cuccurullo" 1 => "G.D. di Stasio" 2 => "L. Evangelista" 3 => "A. Ciarmiello" 4 => "L. Mansi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Esp Med Nucl Imagen Mol" "fecha" => "2018" "volumen" => "37" "paginaInicial" => "103" "paginaFinal" => "109" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "[Article in English, Spanish]" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Value of post-therapy <span class="elsevierStyleSup">177</span>Lu PSMA images for accurate interpretation of therapy response with <span class="elsevierStyleSup">68</span>Ga-PSMA PET/CT" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Tuncel" 1 => "T. Telli" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Esp Med Nucl Imagen Mol" "fecha" => "2018" "volumen" => "37" "paginaInicial" => "114" "paginaFinal" => "117" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Simultaneous whole-body <span class="elsevierStyleSup">18</span>F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.T. Freitag" 1 => "C. Kesch" 2 => "J. Cardinale" 3 => "P. Flechsig" 4 => "R. Floca" 5 => "M. Eiber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-017-3854-6" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2018" "volumen" => "45" "paginaInicial" => "340" "paginaFinal" => "347" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29038888" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical performance of <span class="elsevierStyleSup">68</span>Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Kranzbühler" 1 => "H. Nagel" 2 => "A.S. Becker" 3 => "J. Müller" 4 => "M. Huellner" 5 => "P. Stolzmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-017-3850-x" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2018" "volumen" => "45" "paginaInicial" => "20" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29032394" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000003700000002/v1_201803020417/S2253808918300028/v1_201803020417/en/main.assets" "Apartado" => array:4 [ "identificador" => "7983" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000003700000002/v1_201803020417/S2253808918300028/v1_201803020417/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918300028?idApp=UINPBA00004N" ]
Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación
Esté informado en todo momento gracias a las alertas y novedades
Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados
The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles. The works may be submitted in Spanish or English and are subjected to a peer review process. In 2009, it became the leading Spanish journal in the field of Medical Imaging on having an Impact Factor , awarded by the Journal Citation Reports.
Science Citation Index Expander, Medline, IME, Bibliomed, EMBASE/Excerpta Medica, Healthstar, Cancerlit, Toxine, Inside Conferences, Scopus
See moreThe Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2022
SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.
See moreSNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
See moreRevista Española de Medicina Nuclear e Imagen Molecular (English Edition)
¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?
Are you a health professional able to prescribe or dispense drugs?
Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos